Leana Wen Sells 1,700 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) Director Leana Wen sold 1,700 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $143.35, for a total transaction of $243,695.00. Following the transaction, the director owned 19,739 shares of the company’s stock, valued at $2,829,585.65. This represents a 7.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Glaukos Stock Down 1.8%

Shares of NYSE GKOS opened at $133.36 on Wednesday. The company’s 50-day simple moving average is $114.28 and its 200-day simple moving average is $108.35. Glaukos Corporation has a 52-week low of $73.16 and a 52-week high of $146.75. The firm has a market cap of $7.83 billion, a price-to-earnings ratio of -40.66 and a beta of 0.94. The company has a quick ratio of 4.73, a current ratio of 5.43 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.12. The firm had revenue of $150.57 million during the quarter, compared to the consensus estimate of $137.00 million. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The company’s revenue for the quarter was up 41.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.22) EPS. Equities analysts predict that Glaukos Corporation will post -0.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. JPMorgan Chase & Co. raised their price objective on Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Stifel Nicolaus set a $170.00 price target on shares of Glaukos in a research note on Thursday, April 30th. Wall Street Zen raised shares of Glaukos from a “hold” rating to a “buy” rating in a research note on Saturday. BTIG Research raised their target price on shares of Glaukos from $131.00 to $141.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Finally, Wells Fargo & Company boosted their target price on Glaukos from $135.00 to $138.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $144.42.

Institutional Investors Weigh In On Glaukos

Hedge funds and other institutional investors have recently bought and sold shares of the company. AustralianSuper Pty Ltd grew its stake in shares of Glaukos by 10.8% in the 3rd quarter. AustralianSuper Pty Ltd now owns 449,846 shares of the medical instruments supplier’s stock valued at $36,685,000 after buying an additional 43,750 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Glaukos by 4.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 670,083 shares of the medical instruments supplier’s stock worth $54,645,000 after buying an additional 27,646 shares during the last quarter. SG Americas Securities LLC raised its position in shares of Glaukos by 460.8% during the 4th quarter. SG Americas Securities LLC now owns 60,232 shares of the medical instruments supplier’s stock valued at $6,801,000 after buying an additional 49,492 shares during the period. TD Asset Management Inc acquired a new position in Glaukos in the third quarter valued at approximately $1,157,000. Finally, Allspring Global Investments Holdings LLC lifted its holdings in Glaukos by 32.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 355,279 shares of the medical instruments supplier’s stock valued at $39,336,000 after acquiring an additional 87,781 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Needham reiterated a Buy on Glaukos, reinforcing analyst support and underpinning upside expectations for the shares. Needham Remains a Buy on Glaukos (GKOS)
• Positive Sentiment: Media coverage highlights a shifting narrative as Glaukos gives updated guidance and signals a product ramp (sustained drug-delivery and MIGS growth), which supports upside to revenue trajectory if execution continues. How The Glaukos (GKOS) Narrative Is Shifting With New Guidance And Product Ramp Expectations
• Neutral Sentiment: Recent quarter: revenue beat consensus and EPS outperformed estimates on stronger sales, supporting the case for durable top-line growth even though profitability remains negative. Analysts’ price targets were raised by some firms; consensus remains a Moderate Buy. MarketBeat GKOS summary
• Neutral Sentiment: CFO Alex Thurman sold 10,000 shares under a pre-arranged Rule 10b5-1 plan, which reduces the signal of opportunistic timing but still reduces insider holdings. CFO 10b5-1 sale filing
• Negative Sentiment: COO Joseph Gilliam sold 19,573 shares (~21% reduction in his position), a large insider sale that can raise investor concern about insider confidence or portfolio rebalancing. Glaukos COO Joseph Gilliam Sells 19,573 Shares
• Negative Sentiment: Director Leana Wen sold 1,700 shares, a smaller but visible insider sale disclosed via SEC filing — another factor that can pressure near-term sentiment. Director Leana Wen Sells 1,700 Shares

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.